1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Benefit–risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
- Contribution to journal › Article
- 2011
-
Mark
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
- Contribution to journal › Article